What is Cresilon?
Established in 2010 and headquartered in Brooklyn, United States, Cresilon is dedicated to the development, manufacturing, and marketing of advanced hemostatic medical devices. The company's core innovation lies in its proprietary hydrogel technology, designed to rapidly control bleeding in critical medical situations. This technology positions Cresilon at the forefront of the medical device industry, offering solutions that can significantly improve patient outcomes and streamline surgical procedures. The company's focus on this niche yet vital area of healthcare underscores its strategic importance.
How much funding has Cresilon raised?
Cresilon has raised a total of $68.8M across 4 funding rounds:
Debt
$350K
Series A
$38.5M
Other Financing Round
$25M
Debt
$5M
Debt (2020): $350K with participation from PPP
Series A (2021): $38.5M, investors not publicly disclosed
Other Financing Round (2022): $25M supported by Paulson Investment Company
Debt (2026): $5M, investors not publicly disclosed
Key Investors in Cresilon
Paulson Investment Company
Paulson Investment Company is a boutique investment banking and broker-dealer firm that focuses on serving small and mid-sized companies through capital markets expertise and long-term financial advisory services. The company is built on a foundation of enduring client relationships and emphasizes integrity, diligence, and strategic insight in supporting corporate growth and financing objectives. It operates as a full-service financial intermediary, offering investment banking solutions, private equity-related services, and syndicated offerings designed to help clients access public and private capital markets.
What's next for Cresilon?
With the recent influx of major strategic investment and substantial enterprise-level funding, Cresilon is poised for accelerated growth and market expansion. The capital infusion is expected to fuel further research and development, enhance manufacturing capabilities, and broaden the commercialization of its hemostatic devices. This strategic financing indicates a pivotal stage for Cresilon, likely enabling the company to scale its operations, penetrate new markets, and solidify its position as a leader in advanced wound care and bleeding control solutions. Future developments will likely focus on clinical validation and wider adoption of its groundbreaking technology.
See full Cresilon company page
